Latest Medical Devices News

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Immuron Limited has launched PROIBS®, a new medical device aimed at relieving symptoms of Irritable Bowel Syndrome (IBS), entering a growing Australian market with strong early demand.

Vitasora Health is set to scale its AI-powered chronic care services from Hawaii to 10-15 US states, leveraging a new partnership with Privia Health following Evolent Care Partners' divestiture. This expansion targets up to 30,000 patients and promises significant revenue growth in 2026.

BrainChip Holdings has moved its AKD1500 neuromorphic AI chip into volume production, supported by key supply agreements and expanded distribution channels, while maintaining a stable cash position.